AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05308277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Leo device monitoring
Description: After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
Study NCT05764551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum DNA methylation
Description: Serum DNA methylation
Study NCT05113797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lower Quarter Y-Balance Test
Description: Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
Study NCT05113797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lower Quarter Y-Balance Test
Description: Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
Study NCT05113797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL motor learning theory
Description: OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spermogram
Description: Spermogram will be proposed to men
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: Anxiety and depression will be evaluated 10 years after HSCT
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SF36 Quality of life questionnaire
Description: Quality of life will be evaluated 10 years after HSCT
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychologist interview
Description: During a follow-up visit
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optional sera banking
Description: One in the study
Study NCT06351462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optional DNA banking
Description: Once in the study
Study NCT04759430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Group
Description: Individuals will apply ten different stabilization exercises in company with a physiotherapist.
Study NCT04759430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
Study NCT04428008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Synthetic 28 amino acid peptide
Study NCT06097962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: Intravenous infusion
Study NCT06097962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab，atezolizumab or sugemalimab
Description: Administer according to the instructions
Study NCT06302595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided prostate biopsy using the needle holder frame.
Description: A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
Study NCT05096962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
Study NCT05096962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity
Description: Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
Study NCT05645432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Brexanolone IV infusion
Study NCT05572749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crocus Kozanis
Description: In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.
Study NCT05572749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Crocus Kozanis
Description: Placebo of Crocus Kozanis
Study NCT05572749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
Study NCT05184270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Description: In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted.
Study NCT05323630 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Renuvion APR System
Description: The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
Study NCT04584892 — intervention group
Intervention type: DRUG
Intervention: Turoctocog alfa
Description: Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study NCT05241444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4^LVFOXP3
Description: Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood.
Study NCT05957185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OPTIZIOME® P³ HYDROLYZER® - WHEY
Description: One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
Study NCT05957185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
Study NCT06172790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
Study NCT05981014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT06142435 — intervention group
Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
Study NCT06144944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Description: Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
Study NCT06144944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Description: Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
Study NCT05640167 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interdisciplinary Clinic
Description: Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
Study NCT04287192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Bridge:Tool Intervention
Description: Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
Study NCT04103554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
Study NCT04103554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: standard of care used for treating BP
Study NCT05716737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: 3 Gy in 6 fractions to the TMJ, every other day, LINAC based
Study NCT06078592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIDIN-plus Eye drops
Description: One drop in the eyes, twice a day, approximately 12 hours apart.
Study NCT06078592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combigan Eye drops
Description: One drop in the eyes, twice a day, approximately 12 hours apart.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
Study NCT05981014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D.
Study NCT05981014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study NCT05981014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study NCT06046131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire
Study NCT04183010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise
Study NCT05061199 — intervention group
Intervention type: PROCEDURE
Intervention: approach of anastomosis
Description: The approach of anastomosis
Study NCT05141396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth- enabled support for SAT/SBT adherence
Description: Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
Study NCT05141396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual audit and feedback for SAT/SBT adherence
Description: Usual audit and feedback
Study NCT05141396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual audit and feedback for SAT/SBT adherence
Description: Usual audit and feedback
Study NCT06074692 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Description: Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
Study NCT05272709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.
Study NCT05272709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally, twice daily, for up to 12 months.
Study NCT05282251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacine nebulization
Description: Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
Study NCT05282251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol and ketorolac
Description: Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
Study NCT05194163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW150
Description: oral-delivered capsule of study drug
Study NCT05194163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral delivered capsule matched to study drug capsule
Study NCT06545318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Density Gradient Centrifugation
Description: Sperm separation with density gradients
Study NCT06545318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CA0 chamber
Description: Sperm separation with a novel device
Study NCT04692805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coils
Description: EUS-guided injection of coils
Study NCT04692805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate glue
Description: EUS-guided injection of cyanoacrylate glue
Study NCT06487143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate（15mg）
Description: Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
Study NCT06487143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate （3.75mg）
Description: Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
Study NCT05421156 — intervention group
Intervention type: PROCEDURE
Intervention: Subtotal Laparoscopic Hysterectomy
Description: Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
Study NCT05421156 — intervention group
Intervention type: PROCEDURE
Intervention: Total Laparoscopic Hysterectomy
Description: Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
Study NCT05471440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct boost mRNA
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA
Study NCT05471440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct boost adeno
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno